Investors search for returns in Personalised Medicine
March 11, 2010
Science Business: Helmut Schühsler, head of the life sciences group at Munich-based TVM Capital, believes personalised medicine is the future. But as an investor, he has a problem with it. “It is hard to find investments that make it worth the cost,” he says. “You must always ask yourself, will the exit value be exceeded by what you invest?”